XENETIC BIOSCIENCES, INC. Proceeds from Issuance of Private Placement
XENETIC BIOSCIENCES, INC. (XBIO) reported Proceeds from Issuance of Private Placement of $11.50 million for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-12.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfPrivatePlacement · last filed 2021-11-12
- 2021-09-30: Proceeds from Issuance of Private Placement 9 month $11.50M.
| Period end | Proceeds from Issuance of Private Placement 9 month |
|---|---|
| 2021-09-30 | $11.50M 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |